Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00801632 · ClinicalTrials.gov registry record · Phase 2
Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT00801632: Completed Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00801632 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00801632, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
In small initial studies, combined kidney and bone marrow transplants from the same donor have permitted some individuals to stop taking anti-rejection medicines without rejecting their transplant. This clinical trial will study this method in a greater number of people to determine if it is indeed effective and safe.
Primary Outcome
A participant was considered a success if they were off immunosuppressive therapy for 104 consecutive weeks leading up to study week 208 (48 months post-transplant) or study termination, whichever occurred first.
Interventions
- DRUG cyclophosphamide
- BIOLOGICAL rituximab
- PROCEDURE Kidney Transplantation
- PROCEDURE Bone marrow transplantation
- BIOLOGICAL MEDI-507
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2008-12 |
| Est. Completion | 2014-11 |
| Phase | Phase 2 |
What the finished NCT00801632 record still lists
NCT00801632 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00801632 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00801632 about?
NCT00801632 is a clinical study titled "Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection". In small initial studies, combined kidney and bone marrow transplants from the same donor have permitted some individuals to stop taking anti-rejection medicines without rejecting their transplant. This clinical trial will study this method in a greater number of people to determine if it is indeed ...
What is the current status of trial NCT00801632?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2008-12. Estimated completion is 2014-11.
What interventions are being tested in trial NCT00801632?
The interventions under investigation include: cyclophosphamide (DRUG), rituximab (BIOLOGICAL), Kidney Transplantation (PROCEDURE), Bone marrow transplantation (PROCEDURE), MEDI-507 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00801632?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00801632's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia